1992 年 7 巻 3 号 p. 290-294
In this paper, we present a 27-year-old female of metastatic melanoma treated with interferon-β-DAV combination therapy, and in addition, the course of urine 5-S-cysteinyldopa excretion level was analyzed. Pretreatment urinary excretion level of 5-S-cysteinyldopa was 4, 118.7μg/day and declined immediately after dose. Every after dose, urinary excretion level increased and then decreased rapidly. This fluctuation continued throughout the treatment and the maximum urinary excretion level reached 8, 388μg/day. In comparison of previous reports, this case achieved long-term survival in spite of remarkable high urinary excretion level of 5-S-cysteinyldopa.